In immunocompromised hosts, coronavirus disease 2019 (COVID-19) can span from asymptomatic to severe life-threatening disease. Moreover, chronic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inducing prolonged viral shedding and persistent and/or relapsing symptoms has been reported in these patients.1,2 In chronic SARS-CoV-2 infection, off-label use of remdesivir, convalescent plasma and/or SARS-CoV-2-specific monoclonal antibodies (mAbs) has been anecdotally attempted to reduce disease severity and to achieve viral clearance, with variable results.3,4 Nirmatrelvir/ritonavir is an oral antiviral, which has been proven to reduce by 89% the risk of progression to severe COVID-19 among high-risk patients with early-stage, symptomatic COVID-19.5 Early use of nirmatrelvir/ritonavir has also been shown to shorten time to viral clearance in patients who are immunocompromised and hospitalized with COVID-19.6 To date, there has been limited experience regarding nirmatrelvir/ritonavir efficacy in patients with prolonged and/or relapsing SARS-CoV-2 infection.7 Here we describe three cases of relapsing COVID-19 at the Careggi University Hospital, Florence, Italy, in patients undergoing anti-CD20 immunosuppressant therapy, who showed a successful clinical, virological and radiological response to nirmatrelvir/ritonavir treatment.

Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19 / Graziani, Lucia; Gori, Leonardo; Manciulli, Tommaso; Basile, Gregorio; Campolmi, Irene; Borchi, Beatrice; di Dio, Marta; Mattei, Marta; Ciurleo, Greta; Ciliberti, Maria; Malentacchi, Francesca; Coppi, Marco; Morettini, Alessandro; Parronchi, Paola; Rossolini, Gian Maria; Bartoloni, Alessandro; Tomassetti, Sara; Spinicci, Michele. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - STAMPA. - 78:(2023), pp. 555-558. [10.1093/jac/dkac433]

Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19

Graziani, Lucia;Manciulli, Tommaso;Basile, Gregorio;Campolmi, Irene;di Dio, Marta;Mattei, Marta;Ciurleo, Greta;Malentacchi, Francesca;Coppi, Marco;Morettini, Alessandro;Parronchi, Paola;Rossolini, Gian Maria;Bartoloni, Alessandro;Tomassetti, Sara;Spinicci, Michele
2023

Abstract

In immunocompromised hosts, coronavirus disease 2019 (COVID-19) can span from asymptomatic to severe life-threatening disease. Moreover, chronic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inducing prolonged viral shedding and persistent and/or relapsing symptoms has been reported in these patients.1,2 In chronic SARS-CoV-2 infection, off-label use of remdesivir, convalescent plasma and/or SARS-CoV-2-specific monoclonal antibodies (mAbs) has been anecdotally attempted to reduce disease severity and to achieve viral clearance, with variable results.3,4 Nirmatrelvir/ritonavir is an oral antiviral, which has been proven to reduce by 89% the risk of progression to severe COVID-19 among high-risk patients with early-stage, symptomatic COVID-19.5 Early use of nirmatrelvir/ritonavir has also been shown to shorten time to viral clearance in patients who are immunocompromised and hospitalized with COVID-19.6 To date, there has been limited experience regarding nirmatrelvir/ritonavir efficacy in patients with prolonged and/or relapsing SARS-CoV-2 infection.7 Here we describe three cases of relapsing COVID-19 at the Careggi University Hospital, Florence, Italy, in patients undergoing anti-CD20 immunosuppressant therapy, who showed a successful clinical, virological and radiological response to nirmatrelvir/ritonavir treatment.
2023
78
555
558
Graziani, Lucia; Gori, Leonardo; Manciulli, Tommaso; Basile, Gregorio; Campolmi, Irene; Borchi, Beatrice; di Dio, Marta; Mattei, Marta; Ciurleo, Greta; Ciliberti, Maria; Malentacchi, Francesca; Coppi, Marco; Morettini, Alessandro; Parronchi, Paola; Rossolini, Gian Maria; Bartoloni, Alessandro; Tomassetti, Sara; Spinicci, Michele
File in questo prodotto:
File Dimensione Formato  
dkac433.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 354.83 kB
Formato Adobe PDF
354.83 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1305174
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact